Bayer's Legal Clock Keeps Slipping, Yet the Bullish Case Is Building
Published on 08/17/2026 at 17:22 | Redaktion boerse-global.de
The gap between Wall Street's most cautious and most optimistic views on Bayer has stretched to €17.50 — and the divergence says as much about the company's legal calendar as it does about its operating momentum.
Jefferies, the lone holdout, reaffirmed a "Hold" rating with a €46 price target on August 10. Across the field, the optimists are aiming considerably higher: UBS lifted its target to €62, JPMorgan to €61, and Deutsche Bank to €60, all while maintaining "Buy" or "Overweight" stances. Goldman Sachs now sits at the top of the range with a €63.50 target, raised from €62.50. The flurry of upward revisions followed second-quarter results that landed comfortably ahead of expectations, with operating profit coming in at €2.14 billion against the €1.94 billion consensus cited by Reuters.
A Court Date That Keeps Moving
The immediate catalyst for investor caution isn't the balance sheet — it's a courtroom in Missouri. A hearing to grant final approval to Bayer's multibillion-dollar glyphosate class-action settlement has been pushed back from August 19 to September 14. The joint request from Bayer and plaintiffs' counsel cites the need for additional time to process so-called opt-outs, after some claimants moved to withdraw their exit notices.
That procedural wrinkle traces back to a significant legal development: the U.S. Supreme Court's ruling in Durnell, handed down in late June in favor of Monsanto and, by extension, Bayer. The decision has prompted some plaintiffs to reconsider whether they want to remain in the settlement or pursue individual litigation. Before the court can bless the agreement, it must determine the legal validity of those reversals.
For shareholders, the delay doesn't necessarily signal the deal is in jeopardy — but it does stretch the uncertainty window. The question of how many claimants ultimately participate in the settlement remains unresolved until the September hearing.
Should investors sell immediately? Or is it worth buying Bayer?
The Operating Story Gaining Traction
Underneath the legal noise, the operational narrative is improving. Bayer attributed its quarterly beat to strength in the Crop Science division and pointed to progress on strategic priorities. Management also reaffirmed its 2026 currency-adjusted revenue outlook of €45 billion to €47 billion, alongside adjusted EBITDA guidance of €9.6 billion to €10.1 billion.
The deleveraging story is arguably just as important. Bayer lowered its year-end net debt forecast to €29 billion to €30 billion, down from a prior range of €32 billion to €33 billion. Reuters linked the improvement to the sale of a minority stake to Apollo, and the reduced debt burden gives the company more financial flexibility — a factor analysts likely weighed when revising their targets.
Still, the legal costs are visible in the cash flow statement. Free cash flow swung to minus €2.7 billion in the first half, worse than the minus €1.4 billion recorded a year earlier, with litigation payouts of €2.5 billion accounting for the bulk of the drain.
A Stock Caught Between Two Forces
The share price reflects the tug-of-war. At €48.00, Bayer trades roughly 11 percent below its 52-week high of €53.86, set on July 3. The stock slipped 0.4 percent on the most recent trading day and has lost 2.5 percent over the past seven sessions — yet it remains up 29 percent year to date.
Notably, even Jefferies' conservative €46 target sits below the stock's current level, while the more bullish projections from UBS, JPMorgan, and Goldman Sachs imply substantial upside. The spread between the most bearish and most bullish targets underscores just how much hinges on the legal outcome.
A Defensive Move on the Product Front
Bayer hasn't been idle on the litigation-prevention front. The company has fully switched its Roundup production for the U.S. consumer market to glyphosate-free active ingredients. That shift is designed to curb future claims in the consumer segment, though it does nothing to address the existing wave of lawsuits that the Missouri court will weigh in September.
The practical takeaway for investors: the settlement's ultimate shape — and the timeline for a legally secure resolution — won't become clear until the September 14 hearing. Until then, the stock's valuation will likely continue to oscillate between the improving fundamentals and the unresolved legal overhang.
Ad
Bayer Stock: New Analysis - 17 August
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
